Welcome to Anhui Poly Pharm. Co., Ltd.
language
中文 EN

Deepening Expertise in Key Excipients for Oral Peptides: Anhui Prilly's SNAC with Dual China–US Filings

ScreenShot_2026-11-16_152701_723.png

Foreword

Amid the rapid rise of oral peptide therapeutics, the supply landscape of Sodium 8-(2-hydroxybenzamido)octanoate (SNAC)—a core permeation enhancer in oral semaglutide formulations—has drawn close industry attention. Leveraging more than three decades of international R&D and manufacturing experience from Hainan Poly Pharm, Anhui Prilly Pharmaceutical Co., Ltd. has completed a systematic layout for this product spanning process development, quality research, and dual China–US regulatory filings, offering global formulation clients a stable and compliant excipient option backed by objectively verifiable registration qualifications and production records.

PART.01

Regulatory Filings First: CDE Registration Published, US DMF Review Channel Activated

ScreenShot_2026-11-16_152735_885.png

Anhui Poly's SNAC pharmaceutical excipient completed registration in the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) Excipients, Packaging Materials, and Containers Registration platform on August 6, 2024, with registration number F20240000398. Its current status is "I" (published, pending review triggered by formulation linkage). The registration dossier is complete, covering full process validation and pharmacological/toxicological study data, providing a compliant basis for domestic formulation clients' linked submissions.

Regarding overseas registration, Anhui Poly submitted a Drug Master File (DMF) for SNAC to the US FDA on March 14, 2024, with DMF number 039651. This qualification means Anhui Poly possesses the actual capability to support clients' "dual China–US filings"—formulation clients can directly reference this DMF when filing for the US market without having to wait separately for the excipient supplier's registration progress. Unlike suppliers that have only completed domestic registration and lack a US DMF, this differentiated advantage directly relates to clients' export and dual-filing timelines. Meanwhile, for clients intending to expand into international markets such as the EU, Anhui Poly has established a comprehensive pharmacopoeial applicability quality research system and can readily initiate compliance procedures such as EU ASMF submissions or CEP applications, providing global clients with comprehensive regulatory support.

ScreenShot_2026-11-16_152749_633.png

PART.02

Quality Foundation: Nine GMP Inspections

ScreenShot_2026-11-16_152814_661.png

The reliability of excipient supply is ultimately verified by the compliance history of the manufacturing site. Anhui Poly's SNAC production workshop has passed 3 domestic GMP compliance inspections; the company as a whole has cumulatively passed 9 domestic GMP compliance inspections, demonstrating strong audit acceptability.

At the international regulatory level, the company has passed 2 FDA on-site inspections. In addition, the company passed an audit by Brazil's National Health Surveillance Agency (ANVISA) in April 2026. For formulation clients seeking to assess a supplier's international compliance level, these traceable inspection records constitute an objective reference basis.

PART.03

Toxicological Support: Dual-Track China–US Data Packages Lower the Threshold for Client-Linked Review

ScreenShot_2026-11-16_152828_416.png

As an excipient, the completeness of SNAC's toxicological data directly affects the filing efficiency of formulation clients. Anhui Poly has made targeted preparations in this dimension: on the China side, the registration dossier includes a standalone summary of pharmacological and toxicological studies to support non-clinical safety evaluation; on the US side, the registration dossier contains a complete data package compliant with ICH M4 (and M4Q) requirements. This configuration means that when clients make linked submissions, they do not need to separately supplement or wait for the excipient toxicology portion, thereby reducing—to a certain extent—the number of information requests during the review process.

As the core API and excipient manufacturing base under Hainan Poly Pharm, Anhui Poly will continue to leverage its internationalized quality system and regulatory capabilities to provide global clients with pharmaceutical excipient solutions that withstand audits and regulatory review.

PART.03

About Anhui Poly

undefined

Anhui Poly Pharm. Co., Ltd., founded in 2018, is located in the Anqing National High-Tech Industrial Development Zone. It is a professional supplier of active pharmaceutical ingredients (APIs), providing high-quality specialty raw materials to the global pharmaceutical, healthcare, and skincare industries through chemical synthesis and biotechnological synthesis.

Anhui Poly boasts a strong and highly efficient R&D and production team, is equipped with modern production facilities, and has established a rigorous EU/US high-end API cGMP quality system and a high-standard EHS system. While supplying customers with high-quality APIs and intermediates, the company also offers CDMO services and process technology upgrades. At present, the company has 3 API production workshops compliant with EU, US, and Chinese GMP standards, 10 production lines, and 357 pieces of multi-functional equipment.

Leveraging its strong R&D capabilities and technology transfer expertise, the company has completed the commercial R&D and production of a series of products, including contrast agents (Gadoteric acid meglumine, Gadoteridol, Gadobutrol, Iomeprol, Iopromide, Iohexol, Iopamidol, Iodixanol, etc.), synthetic biology products (Semaglutide, Ectoine, Salidroside), antitumor APIs (Cyclophosphamide), other APIs (Magnesium Hydroxide, Apremilast, Crisaborole, Voriconazole, Memantine Hydrochloride), and other pharmaceutical excipients (DOTA, SNAC, Sulfobutyl-β-cyclodextrin sodium, Calcitetracemate calcium, Cobiprostone calcium).

Since its establishment, Anhui Poly has repeatedly passed official inspections by mainstream international regulatory agencies such as those of China and the United States, and its quality management system's stability and continuous improvement capabilities have been widely recognized.

 

Inquiries and cooperation are welcome!

Business contact: lisubin@hnpoly.com

Disclaimer & Forward-Looking Statement

This article is intended solely for the purposes of pharmaceutical science popularization and corporate information introduction. Its content integrates publicly disclosed materials and summaries of the company's R&D progress and is for reference only. Statements in this article concerning drugs and projects do not constitute medical diagnosis or treatment advice, nor investment advice, nor do they promise any future outcomes. Cooperation arrangements such as contract manufacturing and API supply require the completion of quality system establishment and compliant registration, and are ultimately subject to approval by regulatory authorities. The data and views contained herein are based on publicly available information as of the date of publication of this article, and the company assumes no obligation to continuously update them.

Forward-looking statements in this article concerning regulatory filings, market planning, business development, and the like are all made based on existing information and reasonable assumptions and are subject to uncertainty. Affected by various risk factors such as market conditions and industry policies, actual circumstances may differ materially from expectations. The company has no obligation to revise the relevant content due to subsequent changes. Readers are kindly requested to fully understand the risks and exercise prudent judgment.

Some of the images used in this article are generated by artificial intelligence; please exercise discernment. Some images are sourced from the internet, and copyright belongs to the original authors. If any image used in this article infringes upon your lawful rights and interests, please contact us promptly, and we will verify and delete it.